Febuxostat is indicated as a treatment for gout and hyperuricemia.
The agreement allows Astellas Pharma to sell the product in India, Indonesia, Thailand, the Philippines, Malaysia, Vietnam and Singapore.
Astellas Pharma is responsible for seeking marketing approval in each of these countries, with the goal of beginning sales by 2015.